| Sign In to gain access to subscriptions and/or personal tools. |
DOI: 10.1177/08830738050200071001 © 2005 SAGE Publications Efficacy of Levetiracetam at 12 Months in Children Classified by Seizure Type, Cognitive Status, and Previous Anticonvulsant Drug UseDepartments of Clinical Neurosciences and Pediatrics, Division of Child Neurology, Brown Medical School, Providence, RI, David_Mandelbaum{at}brown.edu.
Department of Pediatrics, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, NJ
Department of Pediatrics, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, NJ
Department of Pediatrics, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, NJ
Department of Pediatrics, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, NJ In a retrospective study of 59 children (ages 9 months to 23 years; mean age 11 years) with intractable epilepsy, seizure frequency was determined before and after 12 months of levetiracetam therapy. Charts were reviewed for seizure type (focal, generalized, or mixed), cognitive function (no special education versus special education), concomitant anticonvulsant medications (range 05), and the number of previous anticonvulsant drugs (range 112). Good to excellent seizure control (50100% reduction) was attained in 6 (40%) patients with focal seizures, 16 (55%) patients with generalized seizures, and 8 (61%) patients with mixed seizures; these efficacy rates were not significantly different. The efficacy of levetiracetam was independent of cognitive status. Adverse effects were not associated with higher mean doses. This could be attributable to different rates of metabolism or represent idiosyncratic responses to the medication. Our finding that those children taking the combination of levetiracetam and zonisamide had a significantly worse outcome than those on levetiracetam and a different drug warrants further study, both clinically and from the standpoint of the mechanisms of action of levetiracetam and zonisamide and/or their pharmacodynamic interactions. (J Child Neurol 2005;20:590594).
This article has been cited by other articles:
|
||||||||||||
